Clene Nanomedicine   Report issue

For profit Phase 2 Phase 3
Founded: Salt Lake City UT United States (2012)

Organization Overview

First Clinical Trial
2015
NCT02755870
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Clene Australia Pty Ltd | Clene Nanomedicine

Active Ingredients

Drugs in Phase 3 Trials (1)

elemental gold (11 trials)

Drugs in Phase 2 Trials (1)

cnm-znag (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Demyelinating Diseases (Phase 2)

Disease Progression (Phase 2)

Motor Neuron Disease (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Neuritis (Phase 2)

Optic Nerve Diseases (Phase 2)

Optic Neuritis (Phase 2)

Parkinson Disease (Phase 2)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 2